This article is more than 5 years old. Information may no longer be current.

Sirion granted orphan drug designation for herpetic keratitis treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

TAMPA, Fla. — Sirion Therapeutics has received orphan drug designation from the U.S. Food and Drug Administration for Virgan, a ganciclovir-based acute herpetic keratitis treatment, the company announced in a press release.

Sirion obtained rights to the drug in January from France-based Laboratoires Thea, which currently markets the drug in Europe. The agreement allows Sirion to market the drug in the United States using the Virgan trade name.